Ticker Details
Corcept Therapeutics Incorporated Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.
IPO Date:	April 14, 2004
Sector:	Healthcare
Industry:	Pharma
Market Cap:	$13.22B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.40 | 2.99%
Avg Daily Range (30 D):	$3.16 | 3.15%
Avg Daily Range (90 D):	$2.03 | 2.55%

Institutional Daily Volume
Avg Daily Volume:	.51M
Avg Daily Volume (30 D):	.89M
Avg Daily Volume (90 D):	.84M

Trade Size
Avg Trade Size (Sh.):	94
Avg Trade Size (Sh.) (30 D):	47
Avg Trade Size (Sh.) (90 D):	46

Institutional Trades
Total Institutional Trades:	5,051
Avg Institutional Trade:	$3.18M
Avg Institutional Trade (30 D):	$9.7M
Avg Institutional Trade (90 D):	$8.02M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.78M
Avg Closing Trade (30 D):	$22.21M
Avg Closing Trade (90 D):	$17.08M
Avg Closing Volume:	146.6K

News

Jul 12, 2026 @ 7:06 PM Corcept Insider Sells Shares After an FDA Approval... Source: Jonathan Ponciano

Jun 4, 2026 @ 5:13 PM State Street SPDR S&P Pharmaceuticals vs First Tru... Source: Brendan Coffey

Apr 21, 2026 @ 7:56 PM INVESTOR ALERT: Pomerantz Law Firm Reminds Investo... Source: Pomerantz Llp

Apr 21, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Corcept Th... Source: Bronstein, Gewirtz & Grossman Llc

Apr 20, 2026 @ 4:59 PM CORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, ... Source: Bragar Eagel & Squire, P.C.

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$1	$.19	$.33
Diluted EPS	$.87	$.16	$.29
Revenue	$741.17M	$207.64M	$194.43M
Gross Profit	$727.78M	$203.04M	$191M
Net Income / Loss	$106.11M	$19.67M	$35.15M
Operating Income / Loss	$65.57M	$10.22M	$26.68M
Cost of Revenue	$13.39M	$4.6M	$3.43M
Net Cash Flow	$-12.15M	$22.39M	$12.93M
PE Ratio